Pharmacovigilance Market

How big is Pharmacovigilance Market in 2026?

Demand is projected to expand at 8.8% CAGR from 2026 to 2036. Market value rises from USD 9 billion in 2025 to USD 9.8 billion in 2026 and USD 22.8 billion by 2036.

The pharmacovigilance market is estimated at USD 9.8 billion in 2026 and is forecast to reach USD 22.8 billion by 2036, with demand expanding at a CAGR of 8.8%. Spending supports the collection, assessment and communication of medicine-safety information across development and commercial use, with the work continuing as products reach larger and more diverse patient populations. WHO describes pharmacovigilance in terms of identifying, understanding and preventing adverse effects and other medicine-related problems, which places scientific assessment alongside the administration of individual reports. [3] Clinical trial programs require organized safety handling while treatments remain under investigation, whereas marketed products generate information from use outside the controlled study setting. FDA notes that preapproval studies cannot anticipate every possible side effect, explaining why surveillance remains necessary after authorization. [1] Purchasers consequently need services and systems that preserve case quality, support timely reporting and allow potential signals to be examined in context. Growth depends on the expansion and complexity of these responsibilities, together with the ability of providers to sustain appropriate oversight across products, languages and jurisdictions.

Key Market Trends & Insights

• Safety teams are connecting case processing with signal assessment so that an increase in incoming reports can be managed without losing clinical context. [2][3]
• Outsourcing remains relevant where sponsors need additional operating capacity, while responsibility for the safety system continues to require clear governance and documented oversight. [2]
• Postmarketing information complements clinical trial findings because medicine use expands to populations and circumstances that cannot all be represented before authorization. [1]

Regional Highlights

• India’s Pharmacovigilance Programme creates an organized route for collecting and assessing adverse drug reactions, with the Indian Pharmacopoeia Commission coordinating the national program. [4]
• European demand operates within EMA good pharmacovigilance practices, which address the safety system, individual case handling, signal management and risk-minimization responsibilities. [2]
• China and Brazil form different expansion markets in the FMI outlook, with service requirements shaped by sponsors needing reliable safety operations across their product portfolios.

Market Size & Forecast

Table 1: Market Size and Forecast for Pharmacovigilance Market (USD billion and percentage), 2025 to 2036

Metric	Value
2025 market value	USD 9 billion
2026 market value	USD 9.8 billion
2036 market value	USD 22.8 billion
CAGR 2026 to 2036	8.8%
Revenue increase 2026 to 2036	USD 13 billion
Market expansion 2026 to 2036	2.33 times

Expansion through 2036 is expected to follow the continuing need to manage product safety across development and marketed use, rather than a single replacement cycle for software. Biologics development adds to the range of products for which sponsors organize safety oversight, while established medicines continue to generate postmarketing information. Providers that combine clinically informed assessment with dependable operational capacity can address both needs, particularly where sponsors require consistent case handling across several jurisdictions and therapeutic portfolios. [1][3]

What responsibilities shape pharmacovigilance service demand?

Pharmacovigilance combines structured reporting with the scientific assessment of whether a safety concern warrants further investigation or action. The usefulness of a case depends on the information available and the ability to assess it alongside other evidence. FDA postmarketing surveillance and EMA good pharmacovigilance practices illustrate why commercial demand includes both operating capacity and specialized judgment. [1][2]

Table 2: Industry evidence relevant to the pharmacovigilance market

Indicator	Data point or observation	Market relevance	Source
Postapproval surveillance	Preapproval studies cannot anticipate every possible adverse effect.	Safety work continues after marketing authorization.	[1]
European safety practices	GVP addresses case reporting, signal management and risk minimization.	Providers need capabilities spanning more than data entry.	[2]
Indian reporting network	PvPI collects and assesses adverse drug reaction information.	Local reporting and clinical context remain relevant to safety operations.	[4]

Analyst Perspective

"Purchasers judge clinical trial pharmacovigilance on qualification effort and lifecycle support."

- Anurag Sharma, Principal Consultant, FMI

How is the Pharmacovigilance Market segmented?

The market is segmented by Type of Pharmacovigilance, Phases, Drug Class, Therapeutic, Delivery Mode, End User, and Region.

The type-of-pharmacovigilance axis distinguishes the purpose and mode of safety surveillance, while the phase axis locates that work before, during or after clinical development. Drug class and therapeutic area influence the clinical information reviewers need to understand, including the different safety questions arising across oncology, immunology and other treatments. Delivery mode identifies how responsibilities are allocated between a sponsor’s own team and outside providers, and end-user coverage shows which organizations purchase or undertake the work. These dimensions help explain why two contracts with similar report volumes may require different medical expertise, follow-up capability and levels of coordination with clinical teams. [1][2][3]

Why does the clinical trial pharmacovigilance segment lead demand by type of pharmacovigilance?

The Clinical Trial Pharmacovigilance segment is projected to account for 28.7% of type of pharmacovigilance demand in 2026.

Table 3: Type of Pharmacovigilance Share for Pharmacovigilance Market (percentage share), 2026

Type of Pharmacovigilance	Estimated share (2026)
Clinical Trial Pharmacovigilance	28.7%
Other type of pharmacovigilance segments	71.3%
Total	100.0%

Table 4: Segment Position and Market Growth for Pharmacovigilance Market, 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	8.8%
Profiled type of pharmacovigilance segment	Clinical Trial Pharmacovigilance

Clinical trial pharmacovigilance supports the assessment of safety while an investigational treatment is being studied, placing it close to decisions about participant protection and the continuing conduct of a development program. Sponsors need consistent handling of information arriving from study sites, with clinical review helping distinguish the significance of an event from the fact that it occurred. [3] The segment’s position reflects this continuing work across programs, including products whose development involves several countries or therapeutic indications. Service selection therefore depends on the ability to maintain case quality, communicate with the study organization and support the applicable reporting responsibilities, rather than simply increasing the number of records processed within a fixed period.

• Clinical Trial Pharmacovigilance is projected to hold 28.7% of demand by type in 2026, reflecting continuing participant-safety assessment and coordination with development programs. [3]
• Clinical review, accurate follow-up and dependable coordination with study teams influence the usefulness of trial-safety services throughout a development program. [3]

Why does the clinical phase segment lead demand by phases?

The Clinical Phase segment is projected to account for 35.0% of phases demand in 2026.

Table 5: Phases Share for Pharmacovigilance Market (percentage share), 2026

Phases	Estimated share (2026)
Clinical Phase	35.0%
Other phases segments	65.0%
Total	100.0%

Clinical phase activity represents the point at which safety information is generated through the exposure of study participants to an investigational product, creating a need for organized collection and assessment throughout the trial. [3] Workloads vary with study design, patient population and the information available about the treatment, so a program cannot be judged by enrollment alone. Sponsors also need communication between clinical operations and safety specialists when a finding may affect the conduct of a study. This combination of continuing operational work and medical interpretation supports the segment’s share of demand. Providers addressing the clinical phase are consequently evaluated on their ability to keep safety information usable as a program develops and its evidence base changes.

• The Clinical Phase is projected to account for 35.0% of phase-based demand in 2026, as participant exposure creates an ongoing need to collect and interpret safety information. [3]
• Safety responsibilities within the clinical phase connect site-level information with medical assessment and the decisions required to protect participants. [3]

What are the drivers, restraints, and opportunities in the Pharmacovigilance Market?

A sponsor gains useful safety capacity when incoming reports remain clinically interpretable through follow-up, review and communication, which makes case quality a practical boundary on the value of automation or outsourcing. Service partners can strengthen their position by showing how operational throughput connects with qualified assessment and sponsor oversight across a product’s development and marketed life. [1][2][3]

Driver

The continuing use of medicines after authorization sustains demand for safety surveillance because wider patient exposure can reveal concerns that were not apparent during development. FDA describes this limitation of preapproval studies within its postmarketing surveillance program. [1] Growth in biosimilar and biologic portfolios also broadens the products requiring organized oversight. For sponsors, the resulting demand combines report handling, clinical assessment and appropriate communication, with requirements continuing across the commercial life of a treatment. [2][3]

Restraint

Incomplete information and inconsistent case quality can make safety assessment difficult even when a reporting system handles substantial volumes. A report of an event also needs clinical context before its relationship with a medicine can be understood. [1][3] Providers must therefore invest in trained review, follow-up and appropriate quality controls, while sponsors retain oversight of outsourced activities. These requirements limit the extent to which lower processing cost alone can determine the choice of a service partner. [2]

Opportunity

Sponsors managing international portfolios can benefit from clearer handoffs between study information, individual safety cases and medical assessment. Clinical trial data management services support the development information from which reviewers may need clinical context, making the interface between those functions relevant to case quality. [3] Within safety operations, providers can improve follow-up and responsibility assignment so that information remains interpretable as a product moves between clinical development and marketed use, while sponsors retain effective oversight of the work. [1][2]

Which country CAGRs are profiled in the Pharmacovigilance Market?

Table 6: Country CAGR Comparison for Pharmacovigilance Market (CAGR percentage), 2026 to 2036

Country	CAGR	Forecast period
China	8.9%	2026 to 2036
India	7.9%	2026 to 2036
Germany	7.3%	2026 to 2036
Brazil	6.0%	2026 to 2036
United States	8.2%	2026 to 2036

Country-wise Analysis

China Pharmacovigilance Market Outlook (2026 to 2036)

China is projected to expand at a CAGR of 8.9% from 2026 to 2036, placing it ahead of the other four profiled markets in the pharmacovigilance outlook. Expansion creates a practical need to coordinate information from clinical development and marketed medicine use, including reports that must remain understandable across local and international safety teams. The scientific purpose remains the assessment of potential medicine-related harm, as described by WHO. [3] Sponsors organizing services for China consequently need appropriate language capability, consistent follow-up and a clear route for medical review. These functions support an operating model in which local case context can be retained while the wider product-safety organization examines emerging information.

India Pharmacovigilance Market Outlook (2026 to 2036)

India’s Pharmacovigilance Programme provides a specific institutional setting for the market, with the Indian Pharmacopoeia Commission acting as the national coordinating center and adverse drug reaction information feeding safety assessment. [4] This reporting network makes the quality of information collected from healthcare settings relevant alongside the activities of pharmaceutical sponsors and their service partners. The Indian market is forecast to grow at a CAGR of 7.9% from 2026 to 2036. Providers working in this environment need to preserve the clinical detail that allows a report to be evaluated, while supporting follow-up when information is incomplete. The opportunity therefore includes dependable coordination with local reporting activity as well as scalable handling of international safety workloads.

Germany Pharmacovigilance Market Outlook (2026 to 2036)

German pharmacovigilance operations sit within the European framework of good pharmacovigilance practices, which gives buyers a defined set of responsibilities covering the safety system, individual reports and signal management. [2] The purchasing requirement is consequently broader than access to a case-processing platform, because sponsors also need evidence that outsourced work remains under appropriate oversight. Germany is projected to record a CAGR of 7.3% from 2026 to 2036. Within this environment, service providers can differentiate through clinically informed assessment and the ability to maintain consistent processes across a product portfolio. Clear responsibility for follow-up and quality review remains relevant when a sponsor divides work between internal specialists and external operating teams.

Brazil Pharmacovigilance Market Outlook (2026 to 2036)

Brazil represents a slower expansion rate than China, India and Germany in the country comparison, with a CAGR of 6.0% projected from 2026 to 2036. The commercial requirement nevertheless includes the same continuing need to understand medicine-safety information as treatments move from trials into wider use. Language and local clinical context can affect how reports are collected and followed up, making coordination with a sponsor’s international safety organization relevant. WHO’s description of pharmacovigilance emphasizes the assessment and prevention of medicine-related problems, which explains why useful operating capacity must preserve more than a completed record. [3] Providers serving Brazil can therefore compete through dependable local handling and a clear route to medical review.

United States Pharmacovigilance Market Outlook (2026 to 2036)

The United States has an established postmarketing surveillance setting in which FDA receives and assesses safety information after medicines have been authorized, recognizing that development studies cannot reveal every possible side effect. [1] This creates continuing work around marketed products in addition to the safety responsibilities of clinical development. Sponsors need to evaluate incoming information in relation to exposure, underlying illness and other available evidence, because an individual report does not by itself establish the cause of an event. Services addressing the United States therefore combine operational handling with qualified review and appropriate follow-up. The United States market is projected at a CAGR of 8.2% from 2026 to 2036, supported by continuing safety oversight throughout a product’s commercial life. [1][2]

Who are the notable companies in the Pharmacovigilance Market?

IQVIA; Parexel International Corporation; ICON plc; PPD; ArisGlobal

Contract research organizations, specialist safety providers and technology companies offer different combinations of medical review, case handling and supporting systems. Healthcare regulatory affairs outsourcing intersects with safety work when sponsors prepare the information and communications required across product jurisdictions, increasing the importance of clear responsibility between functions. [2] Provider comparison can therefore begin with the sponsor’s operating needs, then examine the expertise, information quality and oversight arrangements required to keep safety assessment dependable as workloads and product portfolios change. [2][3]

Competitive Benchmarking: Pharmacovigilance Market

Table 7: Competitive positioning for the pharmacovigilance market

Company	Positioning	Commercial distinction
IQVIA	Life-science safety services and technology	Serves pharmaceutical safety operations through pharmacovigilance services and supporting systems.
Parexel International Corporation	Clinical development and safety services	Supports drug-development programs and their associated safety activities.
ICON plc	Clinical research and safety operations	Participates in outsourced clinical development and pharmacovigilance delivery.
PPD	Contract research and drug-safety services	Addresses sponsor requirements across development and safety operations.
ArisGlobal	Life-science safety software	Provides technology supporting pharmacovigilance information handling and workflows.

Key Developments in the Pharmacovigilance Market

• EMA’s good pharmacovigilance practices framework includes the updated risk-minimization module and related guidance, maintaining a defined reference for the organization of postauthorization safety activities. [2]
• FDA’s postmarketing surveillance program continues to address the limits of preapproval evidence by assessing safety information generated after medicines enter wider clinical use. [1]
• The Indian Pharmacopoeia Commission’s coordinating role in PvPI links adverse drug reaction collection and analysis with recommendations to the national drug regulator. [4]

Key Players in the Pharmacovigilance Market

Life-science safety services and technology

• IQVIA

Clinical development and safety services

• Parexel International Corporation

Clinical research and safety operations

• ICON plc

Contract research and drug-safety services

• PPD

Life-science safety software

• ArisGlobal

Pharmacovigilance Market - Report Scope

Table 8: Report Scope for Pharmacovigilance Market, 2026 to 2036

Coverage field	Report scope
Market	Pharmacovigilance Market
Historical reference year	2025
Base year	2026
Forecast period	2026 to 2036
Quantitative units	USD billion and percentage shares/CAGRs
2026 market value	USD 9.8 billion
2036 market value	USD 22.8 billion
Forecast CAGR	8.8% from 2026 to 2036
Segmentation	type of pharmacovigilance, phases, drug class, therapeutic, delivery mode, end user
Country profiles	China, India, Germany, Brazil, United States

Pharmacovigilance Market - Research Methodology

Table 9: Research Methodology for Pharmacovigilance Market, 2026 edition

Method	Approach
Market definition	Products, services and commercial applications are separated according to their function and purchasing context.
Secondary research	FMI market coverage is assessed alongside official technical guidance, regulatory material and relevant first-party disclosures.
Segmentation	Demand is organized by the stated category axes, retaining the distinction between segment shares and growth rates.
Country assessment	Local care pathways, purchasing conditions and service availability inform the interpretation of each geographic outlook.
Competitive assessment	Participants are compared by relevant offering, customer setting and delivery capability rather than unsupported company rankings.
Consistency review	Market values, forecast periods, units, segment labels and country growth rates are checked for agreement throughout the analysis.

Pharmacovigilance Market by Segments

Pharmacovigilance Market segmented by Type of Pharmacovigilance:

• Clinical Trial Pharmacovigilance
  • Post-Marketing Pharmacovigilance
  • Comparative Pharmacovigilance
  • Herbal and Traditional Medicine Pharmacovigilance
  • Vaccine Pharmacovigilance
  • Targeted Pharmacovigilance
  • Active Pharmacovigilance
  • Passive Pharmacovigilance

Pharmacovigilance Market segmented by Phases:

• Clinical Phase
  • Phase I Trials
    • Phase II Trials
    • Phase III Trials
  • Pre Clinical Phase
    • Safety Data Collection
  • Post Marketing Phase
    • Phase IV Surveillance
    • Real World Evidence Collection

Pharmacovigilance Market segmented by Drug Class:

• Small Molecule Drugs
  • Large Molecule Drugs
  • Herbal & Natural Products

Pharmacovigilance Market segmented by Therapeutic:

• Oncology
  • Cardiology
  • Neurology
  • Immunology & Autoimmune Diseases
  • Gene & Cell Therapy-Related Adverse Events
  • Others

Pharmacovigilance Market segmented by Delivery Mode:

• In-House Pharmacovigilance
  • Internal Pharmacovigilance Teams
  • Outsourced Pharmacovigilance
    • Full Service Outsourcing
    • Functional Service Providers

Pharmacovigilance Market segmented by End User:

• Pharmaceutical Companies
  • Brand Drug Manufacturers
    • Generic Drug Manufacturers
  • Biotechnology Companies
    • Biologic Drug Developers
  • Contract Research Organizations
    • Outsourced Pharmacovigilance Services
  • Business Process Outsourcing Firms
  • Regulatory Authorities
    • Drug Safety Monitoring Agencies
  • Hospitals and Healthcare Providers
    • Clinical Safety Monitoring

Pharmacovigilance Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] US Food and Drug Administration. Accessed 15 October 2026. Postmarketing Surveillance Programs
• [2] European Medicines Agency. Accessed 15 October 2026. Good pharmacovigilance practices
• [3] World Health Organization. Accessed 15 October 2026. Pharmacovigilance
• [4] Indian Pharmacopoeia Commission. Accessed 15 October 2026. Introduction to PvPI

This Report Answers

• How big is the pharmacovigilance market in 2026?
• What is the market outlook through 2036?
• Which segments lead demand in 2026?
• Which countries are examined in the forecast?
• Which companies participate in the market?